Comments on: The next Vioxx trial is on-deck http://www.kevinmd.com/blog/2006/06/next-vioxx-trial-is-on-deck.html medical blog Mon, 22 Mar 2010 02:53:32 -0400 http://wordpress.org/?v=2.8.4 hourly 1 By: Gasman http://www.kevinmd.com/blog/2006/06/next-vioxx-trial-is-on-deck.html/comment-page-1#comment-63776 Gasman Sun, 04 Jun 2006 15:59:00 +0000 http://clients.emmense.com/kevinmd/2006/06/the-next-vioxx-trial-is-on-deck.html#comment-63776 Show me a therapy for arthritis that improve pain and functional status that does not carry some risk. Most antirheumatics have a substantial risk of serious side effects and yet people willingly will trade a risk of death for potential improved funcion. Why should the non-steroidal class of drugs be any different? <br/><br/>The only question is not whether the drugs are a modest risk for cardiovascular outcomes, but whether the company unreasonably prevented this risk from being adequately being weighed by the the patient prior to use. Show me a therapy for arthritis that improve pain and functional status that does not carry some risk. Most antirheumatics have a substantial risk of serious side effects and yet people willingly will trade a risk of death for potential improved funcion. Why should the non-steroidal class of drugs be any different?

The only question is not whether the drugs are a modest risk for cardiovascular outcomes, but whether the company unreasonably prevented this risk from being adequately being weighed by the the patient prior to use.

]]> By: WilliamManginoMd http://www.kevinmd.com/blog/2006/06/next-vioxx-trial-is-on-deck.html/comment-page-1#comment-63758 WilliamManginoMd Sat, 03 Jun 2006 22:05:00 +0000 http://clients.emmense.com/kevinmd/2006/06/the-next-vioxx-trial-is-on-deck.html#comment-63758 This is a pain management issue - and, once again - we must recognize that nonsteroidals carry a certain index associated with important side effects.<br/><br/> Forget, for now, cardiovascular risks; focus on the other side effects.<br/><br/> Mild to moderate doses of opioids should be considered in the mid-elderly with refractory pain. They are safe and not likely to cause addiction. This is a pain management issue – and, once again – we must recognize that nonsteroidals carry a certain index associated with important side effects.

Forget, for now, cardiovascular risks; focus on the other side effects.

Mild to moderate doses of opioids should be considered in the mid-elderly with refractory pain. They are safe and not likely to cause addiction.

]]>